freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-28. Anything still debated is marked as such rather than presented as settled.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Rheumatism (from the Ancient Greek ῥεῦμα, rheûma) or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions. The term "Rheumatic Diseases" is used in MeSH to refer to connective tissue disorders. The branch of medicine devoted to the diagnosis and therapy of rheumatism is called rheumatology.
=== Transcriptional === Insulin acting via the sterol regulatory element binding protein-1c (SREBP1c) is thought to be the most important direct activator of glucokinase gene transcription in hepatocytes. SREBP1c is a basic helix-loop-helix zipper (bHLHZ) transactivator. This class of transactivators bind to the "E box" sequence of genes for a number of regulatory enzymes. The liver promoter in the first exon of the glucokinase gene includes such an E box, which appears to be the principal insulin-response element of the gene in hepatocytes. It was previously thought that SREBP1c must be present for transcription of glucokinase in hepatocytes however, it was recently shown that glucokinase transcription was carried out normally in SREBP1c knock out mice. SREBP1c increases in response to a high-carbohydrate diet, presumed as a direct effect of frequent insulin elevation. Increased transcription can be detected in less than an hour after hepatocytes are exposed to rising insulin levels. Fructose-2,6-bisphosphate (F2,6P2) also stimulates GK transcription, it seems by way of Akt2 rather than SREBP1c. It is not known whether this effect is one of the downstream effects of activation of insulin receptors or independent of insulin action. Levels of F2,6P2 play other amplifying roles in glycolysis in hepatocytes. Other transacting factors suspected of playing a role in liver cell transcription regulation include:
Early histological features expected to be seen on examination of gynecomastic tissue attained by fine-needle aspiration biopsy include the following: proliferation and lengthening of the ducts; an increase in connective tissue; an increase in inflammation; and swelling surrounding the ducts; and an increase in fibroblasts in the connective tissue. Chronic gynecomastia may show different histological features such as increased connective tissue fibrosis, an increase in the number of ducts, less inflammation than in the acute stage of gynecomastia, increased subareolar fat, and hyalinization of the stroma. When surgery is performed, the gland is routinely sent to the lab to confirm the presence of gynecomastia and to check for tumors under a microscope. The utility of pathologic examination of breast tissue removed from male adolescent gynecomastia patients has recently been questioned due to the rarity of breast cancer in this population.
=== Esophageal dysmotility === Presents as a sensation of food getting stuck (dysphagia) in the mid- or lower esophagus, atypical chest pain, or cough. People often state they must drink liquids to swallow solid food. This motility problem results from atrophy of the gastrointestinal tract wall smooth muscle. This change may occur with or without pathologic evidence of significant tissue fibrosis.
Binds to the progesterone receptor (PR) and to an unidentified membrane receptor that drives Prostaglandin E2 (PGE₂) synthesis via COX-2 induction. Induces a feed-forward loop in which PGE₂ amplifies BMP2 expression, accelerating osteogenic and chondrogenic differentiation. Causes sustained phosphorylation of PKCε, an isoform linked to suppression of the hypertrophic cartilage marker MATN1 and to formation of articular-cartilage (interzone) phenotypes. Pharmacological blockade of either PR (mifepristone) or COX-2 (indomethacin) abolishes these effects, confirming that stanozolol’s osteochondral activity requires simultaneous PR signaling and PGE₂-driven crosstalk with the BMP2 pathway. Additionally, stanozolol has been shown to exert activity via estrogen receptor alpha (ERα) in vivo. In a rat model of GnRH agonist-induced growth plate suppression, stanozolol restored chondrocyte proliferation via ERα activation, indicating selective estrogen receptor-mediated effects in growth plate cartilage.
Sources: en.wikipedia.org
The tallest and heaviest dinosaur known from good skeletons is Giraffatitan brancai (previously classified as a species of Brachiosaurus). Its remains were discovered in Tanzania between 1907 and 1912. Bones from several similar-sized individuals were incorporated into the skeleton now mounted and on display at the Museum für Naturkunde in Berlin; this mount is 12 meters (39 ft) tall and 21.8 to 22.5 meters (72 to 74 ft) long, and would have belonged to an animal that weighed between 30000 and 60000 kilograms (70000 and 130000 lb). The longest complete dinosaur is the 27 meters (89 ft) long Diplodocus, which was discovered in Wyoming in the United States and displayed in Pittsburgh's Carnegie Museum of Natural History in 1907. The longest dinosaur known from good fossil material is Patagotitan: the skeleton mount in the American Museum of Natural History in New York is 37 meters (121 ft) long. The Museo Municipal Carmen Funes in Plaza Huincul, Argentina, has an Argentinosaurus reconstructed skeleton mount that is 39.7 meters (130 ft) long.
=== 1.2a === DisplayPort version 1.2a was released in January 2013 and may optionally include VESA's Adaptive Sync. AMD's FreeSync uses the DisplayPort Adaptive-Sync feature for operation. FreeSync was first demonstrated at CES 2014 on a Toshiba Satellite laptop by making use of the Panel-Self-Refresh (PSR) feature from the Embedded DisplayPort standard, and after a proposal from AMD, VESA later adapted the Panel-Self-Refresh feature for use in standalone displays and added it as an optional feature of the main DisplayPort standard under the name "Adaptive-Sync" in version 1.2a. As it is an optional feature, support for Adaptive-Sync is not required for a display to be DisplayPort 1.2a-compliant.
== Side effects == Side effects of methenamine are minor and infrequent, reportedly occurring in fewer than 4% of individuals. They include dyspepsia (upset stomach), abdominal pain, dysuria (painful or uncomfortable urination), nausea, vomiting, diarrhea, headache, rash, and pruritus (itching). The drug is generally very well-tolerated. Rarely, reversibly elevated liver enzymes, including of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported. Normalization of liver enzymes has occurred with discontinuation or continuation of methenamine. Hypersensitivity reactions have also rarely been reported. It has been said that methenamine, overall, is very safe. Formaldehyde is a known carcinogen, for instance being associated with nasopharyngeal cancer and leukemia. This compound also occurs in small amounts as a contaminant in alcoholic beverages, and is chemically similar to the carcinogenic ethanol (alcohol) metabolite acetaldehyde. Because of the formaldehyde exposure with methenamine, there have been concerns about methenamine's potential carcinogenicity and the possibility that it might increase the risk of cancer, for instance bladder or stomach cancer. No clinical studies have looked directly at the long-term effects of methenamine in this regard. However, there are no published case reports documenting incidence of cancer with methenamine as of 2023. Moreover, animal studies have found no evidence of long-term carcinogenicity with oral methenamine.
== Early years == Ned Lagin was born in New York City and raised on Long Island in Roslyn Heights, New York. Growing up, Lagin was influenced by classical and jazz music, and the modern music and art cultures of New York City in the 1960s. He started photography with a Kodak Baby Brownie Special at the age of five, and piano lessons and science, natural history, and electronic projects at the age of six. He attended the Wheatley School in Old Westbury, New York, was awarded two National Science Foundation Scholarships, and attended the Massachusetts Institute of Technology with the intention of becoming an astronaut. Lagin received a degree in molecular biology and humanities from MIT in 1971, where he studied with John Harbison, Gregory Tucker, David Epstein, Noam Chomsky, Gian-Carlo Rota, Salvador Luria, and Jerome Lettvin. Chomsky's generative grammar concepts inspired Lagin's thinking about creating generative music forms (1968), and Lettvin connected him to the writings of Norbert Wiener and Warren McCulloch, and more generally to cybernetics. While at MIT, Lagin also completed jazz coursework at the Berklee School of Music. He was deeply influenced by the jazz world in New York City, particularly pianist Bill Evans, whom he met in Boston and saw perform many times in New York and Boston in the late 1960s and early 1970s. After becoming acquainted with each other, Evans wrote out some of his tunes for Lagin. During this period, his piano teachers included Dean Earl (a former Charlie Parker sideman) and Ray Santisi (a sideman with Parker, Stan Getz and Dexter Gordon).
=== Tumor angiogenesis === AM contributes to tumor angiogenesis, given its capability to enhance smooth muscle and vascular endothelial cell development in addition to its role in ischemic revascularization. Similarly to other solid tumors, AM expression is increased by hypoxia, which has been regarded as an important regulator of tumor development with respect to the findings from animal and in vitro studies, although the translation application to human tumor development is constrained. AM is affiliated with endothelium-derived CC chemokine ligand 2 (CCL2) in the tumor microenvironment, employing genetic deletions and in vivo models to display functional associations. Tumor-derived AM stimulates angiogenesis and promotes tumor growth. Also, endothelial-derived CCL2 decreased AM-induced tumor growth. Deprivation of the AM receptor CALCRL or the G-protein Gs in endothelial cells diminishes both tumor and endothelial cell growth. Removing tumor cell CCR2 or endothelial CCL2 would undo this tumor growth decrease demonstrated in mice without endothelial CALCRL or Gs, displaying a reciprocal regulatory loop between AM and CCL2. AM contributes to cancer pathogenesis through heightened vascularization to equip tumors with nutrients and oxygen, more intense cell phenotypes, and increased cell proliferation. AM receptors (AM1 and AM2) have disparate effects in an array of cancers, with separate regulatory mechanisms and expression patterns.
Sources: en.wikipedia.org
== History == Protein rich in phosphate was discovered early on. In 1906, Levene and Alsberg studied cleavage products of yolk vitellin, and showed that a phosphorus-rich proteinaceous fraction could be obtained from it. In 1933, Fritz Lipmann detected phosphoserine in casein. In 1948, a particularly phosphate-rich protein was isolated from yolk, and it was named phosvitin. Phosphorylase enzymes were discovered later. The first phosphorylase enzyme was discovered by Carl and Gerty Cori in the late 1930s. Carl and Gerty Cori found two forms of glycogen phosphorylase which they named A and B but did not correctly understand the mechanism of the B form to A form conversion. In 1954, another enzyme was discovered, which transfers phosphate from ATP onto a protein. Its physiological function was still not known. Glycogen phosphorylation was better understood later. The interconversion of phosphorylase b to phosphorylase a was described by Edmond Fischer and Edwin Krebs involving a phosphorylation/dephosphorylation mechanism. It was found that an enzyme named phosphorylase kinase and Mg-ATP were required to phosphorylate glycogen phosphorylase by assisting in the transfer of the γ-phosphoryl group of ATP to a serine residue on phosphorylase b. Protein phosphatase 1 is able to catalyze the dephosphorylation of phosphorylated enzymes by removing the phosphate group. Sutherland and Coris discovered epinephrine acts by activating phosphorylase, which leads to the formation of glucose from glycogen.
The first document, which was leaked at the end of January, was a "draft version of the Progressive Conservative government's upcoming health-care transformation legislation." CTV News said "local health integration networks, Cancer Care Ontario, eHealth Ontario, the Trillium Gift of Life Network and other government health agencies" would be "rolled into" the super agency. Minister Elliot said that the December 13 assistant deputy ministers workshop document, which made references to outsourcing laboratories, "inspections, licensing, devices" and Ornge, were options and that these services would not be privatized. The NDP said that the super agency was described in the leaked documents as having the "competency and capacity to effectively partner with public and private sector entities." The documents show that MyCare groups is being created as a "new model" of "integrated care delivery" with the goal of providing "patients with seamless, co-ordinated care and a single team of providers for all their care needs." Ontario Health Minister Christine Elliot tabled the controversial Bill 74: The People's Health Care Act. Its first reading was on February 26, 2019, and it received Royal Assent on April 18, 2019.
== Humans == A typical adult has a blood volume of approximately 5 liters, with females and males having approximately the same blood percentage by weight (approx 7 to 8%) Blood volume is regulated by the kidneys. Blood volume (BV) can be calculated given the hematocrit (HC; the fraction of blood that is red blood cells) and plasma volume (PV), with the hematocrit being regulated via the blood oxygen content regulator:
=== Pharmacokinetics === The time to peak concentrations following a dose is 2 to 4 hours. The typical antidepressant therapeutic range of trimipramine concentrations is 150 to 300 ng/mL. The terminal half-life of trimipramine has been variously reported to be as little as 8 hours (in plasma) and as long as 24 hours. In any case, the terminal half-life of trimipramine is described as shorter than that of other TCAs, which makes it ideal for use in the treatment of insomnia. Trimipramine is a racemic compound with two enantiomers.[1] CYP2C19 is responsible for the demethylation of (D)- and (L)-trimipramine to (D)- (L)-desmethyltrimipramine, respectively, and CYP2D6 is responsible for the 2-hydroxylation of (D)- and (L)-desmethyltrimipramine to (D)- and (L)-2-hydroxydesmethyltrimipramine, respectively. CYP2D6 also metabolizes (L)-trimipramine into (L)-2-hydroxytrimipramine.
=== Pharmacokinetics === It is possible that 2,3-dihydro-LSD may function as a prodrug and aromatize/dehydrogenate into LSD or metabolize into another active metabolite in vivo. Relatedly, 2,3-dihydroindoles can be fairly readily aromatized into indoles, and 2,3-dihydro-LSD has been detected as a metabolite of radiolabeled LSD in the isolated perfused rat liver in vitro, supporting the possibility of interconversion between the two compounds. Alternatively, 2,3-dihydro-LSD might be absorbed more slowly or penetrate the blood–brain barrier more gradually than LSD.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.